PharmiWeb.com - Global Pharma News & Resources

Biotech - Press Releases

Date Title Company
29-Oct-2024 Alira Health Releases Global Report on Trends and Competitive Dynamics in the Biosimilar Market Alira Health
29-Oct-2024 TREMFYA® (Guselkumab) is the first IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn’s disease JOHNSON & JOHNSON
29-Oct-2024 Naobios and Sumagen successfully optimize HIV vaccine candidate for industrial production Andrew Lloyd Associates
28-Oct-2024 Almirall´s 2024 Immunoskin conference hosts leading experts in inflammatory skin conditions to advance science and treatment options Almirall
28-Oct-2024 UPM Biomedicals launches FibGel™ the world’s first injectable nanocellulose hydrogel for medical devices UPM Biomedicals
28-Oct-2024 Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis AstraZeneca
28-Oct-2024 Innovative Trials named a top UK women-powered company in clinical research Innovative Trials
28-Oct-2024 Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 2025 Ottimo Pharma
28-Oct-2024 ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement ProQR
28-Oct-2024 Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance Sanofi
28-Oct-2024 Collaborative Breakthrough in Lung-on-Chip Technology Vitrocell
28-Oct-2024 Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Regeneron
28-Oct-2024 iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress iTeos Therapeutics, Inc
28-Oct-2024 NEW RESEARCH REVEALS LACK OF AWARENESS AROUND ELIGIBILITY FOR WINTER VACCINES Moderna
28-Oct-2024 Innovative back pressure regulator launched by Vapourtec Vapourtec
28-Oct-2024 PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes PolTREG
28-Oct-2024 Duhn Therapeutics, launched by Landmark BioVentures, signs global license agreement with OM Pharma to further advance clinical-stage, lipid-based cancer immunotherapy Duhn Therapeutics
28-Oct-2024 PLL Therapeutics appoints Dr. Souad Kechairi as chief medical officer Andrew Lloyd Associates
28-Oct-2024 HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024 HighTide Therapeutics Inc.
25-Oct-2024 CD Bioparticles Announces New Line of Liposomes for Food Applications CD Bioparticles